TRENDING KEYWORDS
Moderna (MRNA, $151.89) beats Q4 earnings expectations
Moderna posted fourth quarter earnings that surpassed expectations. The pharma company also boosted its full-year revenue outlook for Covid vaccine sales.
and unveiled a new $3 billion share repurchase plan.
Moderna’s diluted GAAP earnings came in at $11.29 per share for the three months ending in December, beating the Street expectations of $9.90 per share. It incurred a loss of -69 cents per share loss in the year-ago quarter.
Revenues of $7.21 billion also exceeded analysts' estimates.
Looking ahead, the company projects sales of its mRNA-1273 coronavirus vaccine, Spikevax , in the region of $19 billion for the year 2022, with additional signed options of approximately $3 billion.
Moderna said that orders have also been confirmed for 2023 from Canada, the United Kingdom and Taiwan.
Momentum Indicator for MRNA turns positive, indicating new upward trend
MRNA saw its Momentum Indicator move above the 0 level on May 25, 2022. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 47 similar instances where the indicator turned positive. In 44 of the 47 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.
Current price $135.80 crossed the support line at $297.00 and is trading between $297.00 support and $115.91 resistance lines. Throughout the month of 04/26/22 - 05/26/22, the price experienced a -7% Downtrend. During the week of 05/19/22 - 05/26/22, the stock fell -5%.
The Stochastic Indicator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 31 of 36 cases where MRNA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.
The Moving Average Convergence Divergence (MACD) for MRNA just turned positive on May 17, 2022. Looking at past instances where MRNA's MACD turned positive, the stock continued to rise in 23 of 28 cases over the following month. The odds of a continued upward trend are 82%.
Following a +11.73% 3-day Advance, the price is estimated to grow further. Considering data from situations where MRNA advanced for three days, in 178 of 203 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.
MRNA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The 10-day Moving Average for MRNA crossed bearishly below the 50-day moving average on April 22, 2022. This indicates that the trend has shifted lower and could be considered a sell signal. In 6 of 9 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 67%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRNA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
The Aroon Indicator for MRNA entered a downward trend on May 23, 2022. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Tickeron has a positive outlook on this ticker and predicts a further increase by more than 4.00% within the next month with a likelihood of 78%. During the last month, the daily ratio of advancing to declining volumes was 1.18 to 1.
The Tickeron Valuation Rating of 59 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.164) is normal, around the industry mean (22.889). P/E Ratio (3.990) is within average values for comparable stocks, (97.651). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.626). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (2.584) is also within normal values, averaging (289.612).
The Tickeron SMR rating for this company is 63 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. MRNA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MRNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
The average market capitalization across the Biotechnology Industry is 1.6B. The market cap for tickers in the group ranges from 2.5K to 243.1B. NONOF holds the highest valuation in this group at 243.1B. The lowest valued company is IMUND at 2.5K.
The average weekly price growth across all stocks in the Biotechnology Industry was 1.15%. For the same Industry, the average monthly price growth was -16.36%, and the average quarterly price growth was -43.39%. MSCLF experienced the highest price growth at 2066.67%, while ATHX experienced the biggest fall at -74.03%.
- 5/25/22 7:32 AM: Moderna (MRNA, $132.06) was a top loser this week, declining -7.18%
- 5/18/22 5:18 AM: Moderna (MRNA, $142.28) was a top weekly gainer, with a +7.53% jump
- 5/5/22 4:57 AM: Moderna (MRNA, $155.05) was a top weekly gainer, with a +8.86% jump
The average weekly volume growth across all stocks in the Biotechnology Industry was 39.88%. For the same stocks of the Industry, the average monthly volume growth was -4.66% and the average quarterly volume growth was -1.88%
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Stocks in the group have a Positive Outlook today, backed by the Volume Indicator. Tickeron has a positive outlook on this group and predicts a further increase by more than 4.00% within the next month with a likelihood of 49%. During the last month, the daily ratio of advancing to declining volumes was 1.42 to 1.
7 stocks in the group of tickers confirmed the positive outlook based on the RSI indicator with average odds of 83%.
The most notable companies in this group are Novavax (NASDAQ:NVAX), BioCryst Pharmaceuticals (NASDAQ:BCRX), Cel-Sci Corp (ASE:CVM).
The average market capitalization across the group is 2.5B. The market cap for tickers in the group ranges from 6.1M to 17.6B. RPRX holds the highest valuation in this group at 17.6B. The lowest valued company is CYTR at 6.1M.
The average weekly price growth across all stocks in the group was -0.05%. For the same group, the average monthly price growth was -1.66%, and the average quarterly price growth was -47.62%. IDRA experienced the highest price growth at 32.12%, while NVAX experienced the biggest fall at -19.44%.
- 5/20/22 5:28 AM: BioCryst Pharmaceuticals (BCRX, $9.03) was a top weekly gainer, with a +14.45% jump
- 5/19/22 8:24 AM: Novavax (NVAX, $52.11) was a top weekly gainer, with a +21.41% jump
- 5/19/22 8:24 AM: Idera Pharmaceuticals (IDRA, $0.44) is a top weekly gainer for penny stocks, rising +39.49%
The average weekly volume growth across all stocks in the group was -9.81%. For the same stocks of the group, the average monthly volume growth was 135.27% and the average quarterly volume growth was 32.28%
- 4/20/22 8:52 AM: The volume for Idera Pharmaceuticals stock increased for one day, resulting in a record-breaking daily growth of 349% of the 65-Day Volume Moving Average
- 3/19/22 4:43 AM: The volume for Agenus stock increased for one day, resulting in a record-breaking daily growth of 249% of the 65-Day Volume Moving Average
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Novavax (NASDAQ:NVAX), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Global Blood Therapeutics (NASDAQ:GBT), Adaptive Biotechnologies Corp (NASDAQ:ADPT).
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
The average market capitalization across the Biotechnology Industry is 1.6B. The market cap for tickers in the group ranges from 2.5K to 241.5B. NONOF holds the highest valuation in this group at 241.5B. The lowest valued company is IMUND at 2.5K.
The average weekly price growth across all stocks in the Biotechnology Industry was -1.5%. For the same Industry, the average monthly price growth was -9.69%, and the average quarterly price growth was -43%. APTCF experienced the highest price growth at 799.09%, while ATHX experienced the biggest fall at -74.48%.
- 5/20/22 5:28 AM: BioCryst Pharmaceuticals (BCRX, $9.03) was a top weekly gainer, with a +14.45% jump
- 5/19/22 8:24 AM: Novavax (NVAX, $52.11) was a top weekly gainer, with a +21.41% jump
- 5/19/22 8:24 AM: Idera Pharmaceuticals (IDRA, $0.44) is a top weekly gainer for penny stocks, rising +39.49%
The average weekly volume growth across all stocks in the Biotechnology Industry was 1.76%. For the same stocks of the Industry, the average monthly volume growth was -11.65% and the average quarterly volume growth was -17.79%
- 4/20/22 8:52 AM: The volume for Idera Pharmaceuticals stock increased for one day, resulting in a record-breaking daily growth of 349% of the 65-Day Volume Moving Average
- 3/19/22 4:43 AM: The volume for Agenus stock increased for one day, resulting in a record-breaking daily growth of 249% of the 65-Day Volume Moving Average
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Latest blogs by Abhoy Sarkar
Top Blogs
